Menopausal hormone therapy for vasomotor symptoms: balancing the risks and benefits with ultra-low doses of estrogen

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.16, Iss.12, 2007-12, pp. : 2005-2020

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Tissue-Selective Estrogen Complex Bazedoxifene and Conjugated Estrogens for the Treatment of Menopausal Vasomotor Symptoms

By Stovall Dale W. Tanner-Kurtz Kirby Pinkerton JoAnn V.

Drugs, Vol. 71, Iss. 13, 2011-09 ,pp. : 1649-1657

Adis International

Access to resources Recommend Favorite

MF101: a multi-component botanical selective estrogen receptor beta modulator for the treatment of menopausal vasomotor symptoms

By Leitman Dale C Christians Uwe

Expert Opinion on Investigational Drugs, Vol. 21, Iss. 7, 2012-07 ,pp. : 1031-1042

Informa Healthcare

Access to resources Recommend Favorite

Drospirenone for Oral Contraception and Hormone Replacement Therapy: Are its Cardiovascular Risks and Benefits the Same as Other Progestogens?

By Motivala Apurva Pitt Bertram

Drugs, Vol. 67, Iss. 5, 2007-01 ,pp. : 647-655

Adis International

Access to resources Recommend Favorite

Tissue-Selective Estrogen Complexes: A Promising Option for the Comprehensive Management of Menopausal Symptoms

By Archer David F.

Drugs & Aging, Vol. 27, Iss. 7, 2010-07 ,pp. : 533-544

Adis International

Access to resources Recommend Favorite

The pharmacogenomics of sex hormone metabolism: breast cancer risk in menopausal hormone therapy

By Justenhoven Christina Obazee Ofure Brauch Hiltrud

Pharmacogenomics, Vol. 13, Iss. 6, 2012-04 ,pp. : 659-675

Future Medicine

Access to resources Recommend Favorite